Status:
UNKNOWN
The Role of Ischemia Modified Albumin in Patients With COVID-19
Lead Sponsor:
Larissa University Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to recognize the diagnostic and/or prognostic value of IMA, as It reflects the degree of ischemia regardless of the affected organ. Our sample, which will be taken from th...
Detailed Description
Endothelial activation and dysfunction are associated with COVID-19 severity. Epidemiological studies suggest that severe cases or deaths due to COVID-19 frequently present with underlying comorbiditi...
Eligibility Criteria
Inclusion
- \> 18 years old
- Positive nasopharyngeal test for SARS-CoV-2 confirmed by RT-PCR
Exclusion
- Age \< 18 years old
- SARS-CoV-2 infection not confirmed by RT PCR
- No consent for participation in the study
- Acute ischemic disease prior to SARS-CoV-2 (trauma, mesenteric ischemia, stroke, liver disease, venous thromboembolic disease, acute coronary syndrome in the last 3 months, etc.)
- Pregnancy
- Immunosuppression
- Albumin \< 2gr/dl or \> 5.5gr/dl
Key Trial Info
Start Date :
April 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT05286268
Start Date
April 6 2022
End Date
July 1 2022
Last Update
May 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Larissa University Hospital
Larissa, Thessaly, Greece, 41334